Neural transplantation of genetically modified cells has been successfully employed to reverse functional deficits in animal models of neurodegenerative disorders, including Parkinson's disease. While implanted PC12 cells secrete dopamine in vivo and can ameliorate dopamine deficiency in parkinsonian rat model systems, these cells either degenerate within 2-3 wk postimplantation (presumably due to the lack of neural trophic factor support at the site of implantation), or in some cases, form a tumor mass leading to the death of the host animal. To address these limitations, we have developed a genetically modified PC12 cell line that can synthesize nerve growth factor (NGF) under the control of a zinc-inducible metallothionein promoter. When implanted in the rat striatum and under in vivo zinc stimulation, these cells will neurodifferentiate, express tyrosine hydroxylase, and will undergo survival through potential autocrine trophic support. This regulatable cell line and general approach may provide additional insight on the potential utilization of cell transplants for treatment of Parkinson's disease and other neurodegenerative disorders.
AusubelF.; BrentR.; KingstonR.; MooreD.; SeidmanJ.; SmithJ.; StruhlK., eds. Current protocols in molecular biology.New York: John Wiley and Sons; 1987.
2.
BjorklundA.; KromerL.F.; SteneviU.Cholinergic reinnervation of the rat hippocampus by septal implants is stimulated by perforant path lesion.Brain Res.173: 57–64; 1979.
3.
BjorklundA.; SteneviU.Intracerebral neural implants: Neuronal implants and reconstruction of damaged circuitries.Ann. Rev. Neurosci.7: 279–308; 1984.
4.
ChenC.; OkayamaH.Calcium phosphate-mediated gene transfer: A highly efficient system for stably transforming cells with plasmid DNA.Mol. Cell. Biol.66: 632–638; 1988.
5.
ChengB.; MattsonM.P.Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: Prevention by NGF and bFGF.Exp. Neurol.117: 114–123; 1992.
6.
CunninghamL.A.; ShortM.P.; BreakefieldX.O.; BohnM.C.Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease.Brain Res.658: 219–231; 1994.
7.
CunninghamL.A.; ShortM.P.; VielkindU.; BreakefieldX.O.; BohnM.C.Survival and differentiation within the adult mouse striatum of grafted rat pheochromocytoma cells (PC 12) genetically modified to express recombinant β-NGF.Exp. Neurol.112: 174–182; 1991.
8.
DunnettS.B.; LowW.C.; IversenS.D.; SteneviU.; BjorklundA.Septal transplants restore maze learning in rats with fornix-fimbria lesions.Brain Res.251: 335–348; 1982.
9.
EmerichD.F.; McDermottP.E.; KruegerP.M.; FrydelB.; SanbergP.R.; WinnS.R.Polymer-encapsulated PC12 cells promote recovery of motor function in aged rats.Exp. Neurol.122: 37–47; 1993.
10.
ErnforsP.; EbendalT.; OlsonL.; MoutonP.; StrombergI.; PerssonH.A cell line producing recombinant nerve growth responses in intrinsic and grafted central cholinergic neurons.Proc. Natl. Acad. Sci.86: 4756–4760; 1989.
11.
FreedW.J.; HofferB.J.; OlsonL.; WyattR. J.Transplantation of catecholamine containing tissues to restore functional capacity to the damaged nigrostriatal system. In: SladekJ.R.Jr.; GashD.M., eds. Neural transplants: Development and function.New York: Plenum Press; 1983: 373–406.
12.
FreedW.J.; Patel-VaidyaU.; GellerH.M.Properties of PC 12 pheochromocytoma cells transplanted to the adult rat brain.Exp. Brain Res.63: 557–566; 1986.
GashD.M.; NotterM.F.D.; OkawaraS.H.; KrausA.L.; JoyntR.J.Amitotic neuroblastoma cells used for neural implants in monkeys.Science233: 1420–1422; 1986.
15.
HeftiF.; HartikkaJ.; SchlumpfM.Implantation of PC12 cells into the corpus striatum of rats with lesions of the dopaminergic nigrostriatal neurons.Brain Res.348: 283–288; 1985.
16.
HempeJ.M.; CarlsonJ.M.; CousinsR.J.Intestinal metallothionein gene expression and zinc absorption in rats are zinc-responsive but refractory to dexamethasone and interleukin 1 alpha.J. Nutrit.121: 1389–1396: 1991.
17.
HorellouP.; BrundinP.; KalenP.; MalletJ.; BjorklundA.Grafts of genetically engineered cells with a recombinant retrovirus encoding human tyrosine hydroxylase: Behavioral effects and in vivo release of dopa and dopamine in a rat model of Parkinson's disease. In: LindvallO.; BjorklundA.; WidmerH., eds. Intracerebral transplantation in movement disorders.New York: Elsevier; 1991: 259–27.
18.
Hou-YuA.; EhlichP.H.; ValiquetteG.; EngelhardtD.L.; SawyerW.H.; NilaverG.; ZimmermanE.A.A monoclonal antibody to vasopressin: Preparation, characterization, and application in immunocytochemistry.J. Histochem. Cytochem.30: 1249–1260; 1982.
19.
JunardE.O.; MonteroC.N.; HeftiF.Long-term administration of mouse nerve growth factor to adult rats with partial lesions of the cholinergic septo-hippocampal pathway.Exp. Neurol.110: 25–38; 1990.
20.
KawajaM.D.; RosenbergM.B.; YoshidaK.; GageF.H.Somatic gene transfer of nerve growth factor promotes the survival of axotomized septal neurons and the regeneration of their axons in adult rats.J. Neurosci.12: 2849–2864; 1992.
21.
KordowerJ.H.; FiandacaM.S.; NotterM.F.D.; HansenJ.T.; GashD.M.NGF-like trophic support from peripheral nerve for grafted rhesus adrenal chromaffin cells.J. Neurosurg.73: 418–428; 1990.
22.
LeeV.M.Y.; PageC.The dynamics of nerve growth factor-induced neurofilament and vimentin filament expression and organization in PC12 cells.J. Neurosci.4: 1705–1714; 1984.
23.
LeonardD.G.B.; ZiffE.B.; GreeneL.A.Identification and characterization of mRNAs regulated by nerve growth factor in PC12 cells.Mol. Cell Biol.7: 3156–3167; 1987.
24.
LindvallO.; RehncronaS.; BrundinP.; GustaviiB.; AstedtB.; WindnerH.; LindholmT.; BjorklundA.; KeendersK.L.; RothwellJ.C.Human fetal dopamine neurons grafted into the striatum of two patients with severe Parkinson's disease.A detailed account of methodology and a six-month follow-up. Arch. Neurol.46: 615–31; 1989.
25.
Lopez-LozanoJ.J.; BravoG.; AbascalJ.Grafting of perfused adrenal medullary tissue into the caudate nucleus of patients with Parkinson's disease.J. Neurosurg.75: 234–243; 1991.
26.
MargolskeeR.F.; KavathasP.; BergP.Epstein-Barr virus shuttle vector for stable episomal replication of cDNA expression libraries in human cells.Mol. Cell. Biol.8: 2837–2847; 1988.
27.
MilbrandtJ.Nerve growth factor rapidly induces c-fos mRNA in PC 12 rat pheochromocytoma cells.Proc. Natl. Acad. Sci. USA83: 4789–4793; 1986.
28.
NilaverG.; KozlowskiG.P.Comparison of the PAP and ABC immunocytochemical techniques. In: BullockG.R.; PetruszP., eds. Techniques in immunocytochemistry. Vol. 4. London: Academic Press; 1989: 199–215.
29.
PaxinosG.; WatsonC.The rat brain in stereotactic coordinates.2nd ed.New York: Academic Press; 1986.
30.
PlunkettR.J.; BankewiczK.S.; CumminsA.C.; MiletichR.S.; SchwartzJ.P.; OldfieldE.H.Long-term evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone.J. Neurosurg.73: 918–926; 1990.
31.
ScottJ.; SelbyM.; UrdeaM.; QuirogaM.; BellG.I.; RutterW.J.Isolation and nucleotide sequence of a cDNA encoding the precursor of nerve growth factor.Nature.302: 538–540; 1983.
32.
SeldenR.F.; SkoskiewiczM.J.; HowieK.B.; RussellP.S.; GoodmanH.M.Implantation of genetically engineered fibroblasts into mice: Implications for gene therapy.Science236: 714–718; 1987.
33.
ShortM.P.; RosenbergM.B.; EzzedineZ.D.; GageF.H.; FriedmanT.; BreakefieldX.O.Autocrine differentiation of PC12 cells mediated by retroviral vectors.Dev. Neurosci.12: 128–133; 1990.
34.
SilaniV.; FaliniA.; StradaO.; PizzutiA.; PezzolG.; MottiE.D.; VegetoA.; ScarlatoG.Effects of nerve growth factor in adrenal autografts in parkinsonism.Ann. Neurol.27: 341–342; 1990.
35.
SladekJ.R.; GashD.M.Nerve-cell grafting in Parkinson's disease.J. Neurosurg.68: 337–351; 1988.
36.
TakeuchiJ.; TakebeY.; SakakuraT.; HaraT.; YasudaT.; ImaiT.Adrenal medulla transplantation into the putamen in Parkinson's disease.Neurosurgery26: 499–503; 1990.
